Key result
Tolvaptan linked to safe improvement of prolonged CHF and urine volume after cardiac surgery.
Why the study?
The safety and efficacy of tolvaptan for prolonged severe congestive heart failure after cardiac surgery were not established.
Case Report (n=1)
No
Tolvaptan may be a safe and effective adjunctive therapy for prolonged severe congestive heart failure following cardiac surgery.
Hypothesis-generating for tolvaptan in post-cardiac surgery congestion; prospective trials needed before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yoshitake et al. (2014) conducted a case report in Postoperative congestive heart failure (n=1). Tolvaptan was evaluated on Improvement of congestive heart failure and urine volume. Administration of tolvaptan for 5 days safely and effectively increased urine volume and improved prolonged congestive heart failure after cardiac surgery without worsening hemodynamics or renal function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: